The Martin Delaney Collaboratories for HIV Cure Research is the flagship NIH program on HIV cure research. The purpose is to foster dynamic, multidisciplinary collaborations between basic, applied, and clinical researchers studying HIV persistence and developing potential curative strategies. This is accomplished by establishing partnerships across academia, industry, government, and community, with a goal of leveraging common resources to accelerate the pace of HIV cure research and engage the next generation of HIV cure researchers.
The program was launched in July 2011 with the funding of three Collaboratories: CARE, DARE, and defeatHIV. In July 2016, the program was expanded to include three additional Collaboratories (BELIEVE, BEAT-HIV, and I4C) for a total of six Collaboratories. In 2021, the program was further expanded to include a total of 10 Collaboratories (CARE, DARE, BEAT-HIV, I4C, REACH, ERASE-HIV, CRISPR for Cure, PAVE, RID-HIV, and HOPE), with one of them (PAVE) focused specifically on HIV cure research in infants and children. The combined program supports a network of approximately 300 Collaboratory members.
Main Areas of Focus
- Basic and clinical research to characterize persistent HIV reservoirs and to determine the mechanisms associated with viral latency, post-treatment control, and viral rebound
- Applied research to develop and test therapeutic strategies for eradicating or controlling residual virus using in vitro, ex vivo, and animal models
- Designing clinical trial protocols to test safety, tolerability, and initial proof-of-concept of curative therapies
- Community engagement to advance research literacy, set realistic expectations of success, and address potential concerns regarding acceptability, enrollment, safety, or ethics
The Pathogenesis and Basic Research Branch and the Targeted Interventions Branch of the Basic Sciences Program in DAIDS coordinate with the Maternal, Adolescent and Pediatric Research Branch of the Prevention Sciences Program in DAIDS to oversee the MDC program by convening an MDC Program Management Team made up of representatives from other Branches, Programs, and Divisions of NIAID, along with the co-funding Institutes (NICHD, NIDA, NIMH, NIDDK, NHLBI, and NINDS) and the NIH Office of AIDS Research.
Joint MDC Satellite Meeting, December 13, 2022 (held in conjunction with the 2022 HIV Persistence During Therapy International Workshop)
Strategies for an HIV Cure, October 12-13, 2023, Natcher Conference Center, NIH Main Campus, Bethesda, MD
Grantee institutions: Beth Israel Deaconess Medical Center, Emory University, Gladstone Institutes, Johns Hopkins University, Scripps Research, Temple University, University of California San Francisco, The University of North Carolina at Chapel Hill, Weill Cornell Medicine, The Wistar Institute.
Karl Salzwedel – Chief, Pathogenesis and Basic Research Branch, DAIDS
Sandra Bridges – Chief, Targeted Interventions Branch, DAIDS
Patrick Jean-Philippe – Chief, Maternal, Adolescent and Pediatric Research Branch, DAIDS